Acushnet Holdings Corp. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Acushnet Holdings Corp. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $1.63B | Feb 28, 2019 |
| FY2018 | Dec 31, 2017 | $1.56B | Feb 28, 2019 |
| FY2018 | Dec 31, 2016 | $1.57B | Feb 28, 2019 |
| FY2017 | Dec 31, 2015 | $1.50B | Mar 7, 2018 |
| FY2016 | Dec 31, 2014 | $1.54B | Mar 30, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.56B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $2.46B | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $2.38B | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $2.27B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $2.15B | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | $420.49M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $482.93M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $300.00M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $408.74M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $368.27M | Feb 25, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $351.39M | Mar 7, 2018 |
| FY2017 | Sep 30, 2017 | $347.26M | Mar 7, 2018 |
| FY2017 | Jun 30, 2017 | $427.99M | Mar 7, 2018 |
| FY2017 | Mar 31, 2017 | $433.62M | Mar 7, 2018 |
| FY2017 | Dec 31, 2016 | $329.76M | Mar 7, 2018 |
| FY2017 | Sep 30, 2016 | $339.32M | Mar 7, 2018 |
| FY2017 | Jun 30, 2016 | $463.26M | Mar 7, 2018 |
| FY2017 | Mar 31, 2016 | $439.94M | Mar 7, 2018 |
| FY2016 | Dec 31, 2015 | $320.22M | Mar 30, 2017 |
| FY2016 | Sep 30, 2015 | $319.87M | Mar 30, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.22B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.19B | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $1.12B | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $1.05B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $1.12B | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | $220.40M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $252.02M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $156.46M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $200.96M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $186.69M | Feb 25, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $188.55M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $214.30M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $198.43M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $199.28M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $178.87M | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | $21.60M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $63.22M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $2.31M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $8.88M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $17.86M | Feb 25, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $299.43M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $304.26M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $285.31M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $281.53M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $259.81M | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | $27.09M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $85.20M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $11.73M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $21.43M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $28.57M | Feb 25, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $76.51M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $67.84M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $64.84M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $56.39M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $55.34M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $48.94M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $51.60M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $51.49M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $47.24M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $48.13M | Feb 28, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $833.42M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $801.60M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $755.67M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $702.88M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $795.42M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $610.60M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $627.50M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $611.88M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $578.29M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $600.09M | Feb 28, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $194.37M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $245.11M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $371.83M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($67.79M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $314.12M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $264.43M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $134.28M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $163.73M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($27.04M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $104.27M | Feb 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $74.34M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $74.62M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $75.36M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $61.36M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $37.60M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $24.68M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $32.96M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $32.80M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $18.85M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $19.18M | Feb 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.34B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $2.18B | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $2.20B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $2.19B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $2.01B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $1.87B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $1.82B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $1.69B | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $1.73B | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $1.74B | Mar 7, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.56B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.38B | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $1.28B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.21B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $922.27M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $849.18M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $865.42M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $764.64M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $879.93M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $967.35M | Mar 7, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $783.57M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $765.25M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $864.24M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $939.06M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.04B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $983.95M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $918.44M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $894.87M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $821.31M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $735.87M | Mar 7, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $224.26M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $220.14M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $225.30M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $224.81M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $210.43M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $215.19M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $214.06M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $209.67M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $203.40M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $196.70M | Feb 28, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $141.96M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $180.28M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $159.91M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $473.13M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $324.97M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $199.78M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $151.04M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $72.95M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $8.20M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | ($53.95M) | Mar 7, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $76.06M | Mar 30, 2017 |
| FY2016 | Dec 31, 2015 | $54.41M | Mar 30, 2017 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $933.40M | Feb 27, 2026 |
| FY2024 | Dec 31, 2024 | $757.51M | Feb 27, 2025 |
| FY2023 | Dec 31, 2023 | $676.73M | Feb 29, 2024 |
| FY2022 | Dec 31, 2022 | $526.31M | Mar 1, 2023 |
| FY2021 | Dec 31, 2021 | $315.00M | Mar 1, 2022 |
| FY2020 | Dec 31, 2020 | $332.50M | Feb 25, 2021 |
| FY2019 | Dec 31, 2019 | $350.00M | Feb 27, 2020 |
| FY2018 | Dec 31, 2018 | $384.84M | Feb 28, 2019 |
| FY2017 | Dec 31, 2017 | $446.56M | Mar 7, 2018 |
| FY2016 | Dec 31, 2016 | $370.31M | Mar 30, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 25, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 25, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | 74.76M | Feb 28, 2019 |
| FY2018 | Dec 31, 2017 | 74.48M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | 74.09M | Mar 7, 2018 |
| FY2016 | Dec 31, 2015 | 21.82M | Mar 30, 2017 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $56.16M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $54.29M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $52.48M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $52.24M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $49.17M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $46.07M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $43.49M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $39.06M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $35.74M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $0 | Feb 28, 2019 |